摘要 |
The present invention relates to compounds of Formula (I) or (II), or a pharmaceutically acceptable salt, ester, or prodrug, thereof: formula (I), formula (II): which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. |
申请人 |
ENANTA PHARMACEUTICALS, INC.;NAKAJIMA, SUANNE;SUN, YING;TANG, DATONG;XU, GOUYOU;PORTER, BRIAN;OR, YAT, SUN;WANG, ZHE;MIAO, ZHENWEI |
发明人 |
NAKAJIMA, SUANNE;SUN, YING;TANG, DATONG;XU, GOUYOU;PORTER, BRIAN;OR, YAT, SUN;WANG, ZHE;MIAO, ZHENWEI |